Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01500902|
Recruitment Status : Completed
First Posted : December 29, 2011
Last Update Posted : September 23, 2015
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome||Other: EndoPAT testing (non invasive device) Other: WatchPAT testing (non-invasive device)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||101 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Assessment of Novel Functional Risk Factors for the Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||April 2015|
We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
Other: EndoPAT testing (non invasive device)
Using the EndoPAT device, we will assess endothelial function.
Other Name: Itamar EndoPAT 2000
Other: WatchPAT testing (non-invasive device)
Using the WATCHPAT device we will assess sleep apnea.
Other Name: Itamar WatchPAT 200
- Unstable Angina, Myocardial Infarction, Repeat Revascularization, Cardiac Death, Stroke [ Time Frame: Will determine with statistical analysis after all patients have had 2 year follow-up ]
- Quality of Life [ Time Frame: 6 months post revascularization. ]Quality of Life as assessed by SF12
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01500902
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Amir Lerman, M.D.||Mayo Clinic|